We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+35.24%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$9.32B
AUM Growth
+$2.47B
Cap. Flow
+$393M
Cap. Flow %
4.22%
Top 10 Hldgs %
43.12%
Holding
161
New
36
Increased
24
Reduced
14
Closed
22

Top Buys

Rank Stock Value
1
NVTA
Invitae Corporation
NVTA
+$348M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$229M
3
AVIR icon
Atea Pharmaceuticals
AVIR
+$100M
4
CCCC icon
C4 Therapeutics
CCCC
+$91.6M
5
KRON
Kronos Bio
KRON
+$87.2M

Top Sells

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$190M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$112M
3
IMMU
Immunomedics Inc
IMMU
+$77.6M
4
BPMC
Blueprint Medicines
BPMC
+$61.6M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$36.5M

Sector Composition

Rank Sector Weight
1 Healthcare 85.2%
2 Financials 0.33%
3 Industrials 0.29%
4 Materials 0.22%
5 Consumer Discretionary 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNCE
126
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$3.2M 0.03%
+15,000
New +$3.12M
ADAP
127
DELISTED
Adaptimmune Therapeutics
ADAP
$2.16M 0.02%
400,000
– –
EIGR
128
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.72M 0.02%
4,663
– –
RACE icon
129
Ferrari
RACE
$67.8B
$1.42M 0.02%
6,200
– –
SRRA
130
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$1.07M 0.01%
66,655
– –
VINCW
131
DELISTED
Vincerx Pharma, Inc. Warrant
VINCW
$990K 0.01%
+300,000
New +$998K
ABCL icon
132
AbCellera Biologics
ABCL
$1.65B
$805K 0.01%
+20,000
New +$915K
LEGN icon
133
Legend Biotech
LEGN
$3.65B
$704K 0.01%
25,000
– –
IPOF
134
DELISTED
Social Capital Hedosophia Holdings Corp. VI
IPOF
$671K 0.01%
+40,000
New +$455K
CMAX
135
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$312K ﹤0.01%
+667
New +$224K
OTLKW
136
DELISTED
Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
$93K ﹤0.01%
420,875
– –
AKRO
137
DELISTED
Akero Therapeutics
AKRO
– –
-21,938
Closed -$675K
ATEC icon
138
Alphatec Holdings
ATEC
$1.48B
– –
-561,574
Closed -$3.73M
ATRC icon
139
AtriCure
ATRC
$2.08B
– –
-216,449
Closed -$8.64M
BIIB icon
140
CALL
Biogen
BIIB
$30.9B
– –
-100,000
Closed -$28.4M
BIO icon
141
Bio-Rad Laboratories Class A
BIO
$8.76B
– –
-489
Closed -$252K
BPMC
142
DELISTED
Blueprint Medicines
BPMC
– –
-664,574
Closed -$61.6M
CLDX icon
143
Celldex Therapeutics
CLDX
$2.94B
– –
-49,751
Closed -$738K
CRSP icon
144
CRISPR Therapeutics
CRSP
$4.69B
– –
-1,341,308
Closed -$112M
HOLX
145
DELISTED
Hologic
HOLX
– –
-170,000
Closed -$11.3M
PODD icon
146
Insulet
PODD
$11.8B
– –
-37,733
Closed -$8.93M
PSNL icon
147
Personalis
PSNL
$1.25B
– –
-27,272
Closed -$591K
REPL icon
148
Replimune Group
REPL
$454M
– –
-19,230
Closed -$443K
TGTX icon
149
TG Therapeutics
TGTX
$8.19B
– –
-33,893
Closed -$907K
TWST icon
150
Twist Bioscience
TWST
$5.32B
– –
-112,756
Closed -$8.57M
3 4 5
6
7

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q4 2020 Portfolio in Review

As of Q4 2020, Perceptive Advisors held 161 positions worth $9.32B, up 36% from $6.85B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Perceptive Advisors deployed $393M of net new capital in Q4 2020, opening 36 new positions and adding to 24 existing holdings. Its largest new stake was Invitae Corporation: 7,284,466 shares worth $305M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 82% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Iovance Biotherapeutics, an estimated $36.5M trimmed.

  • Perceptive Advisors's largest Q4 2020 buy was Invitae Corporation: 7,284,466 shares worth $305M.
  • Perceptive Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q4 2020, an estimated $55.8M increase.
  • Perceptive Advisors's biggest Q4 2020 reduction was Iovance Biotherapeutics, cutting an estimated $36.5M.
  • Perceptive Advisors fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $190M.
  • Perceptive Advisors's ten largest holdings make up 43% of its $9.32B portfolio in Q4 2020.
  • Perceptive Advisors opened 36 new positions and closed 22 in Q4 2020.
  • Perceptive Advisors's portfolio value rose 36% quarter-over-quarter to $9.32B.

Based on Perceptive Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.